Puma Biotechnology reports Q4 GAAP net income $19.3M ($0.39 EPS); guides FY2025 net income $23-28M

PUMA BIOTECHNOLOGY, INC.

2024-FY EPS reported $0.62 revenue$230,468,000

Q4 product revenue net $54.4M (up from $53.2M YoY); full year $195.2M (down from $203.1M).
GAAP net income $30.3M ($0.62/share) for FY2024 vs. $21.6M ($0.46) in FY2023.
Non-GAAP adjusted net income $38.5M ($0.79/share) for FY2024 vs. $31.8M ($0.68) in FY2023.
Cash and securities $101M at Dec 31, 2024; operating cash flow $38.9M for FY2024.
FY2025 guidance: net product revenue $192-198M; net income $23-28M (excludes valuation allowance).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.